Process for preparing dispersion powders
US-9815977-B2 · Nov 14, 2017 · US
US9566243B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9566243-B2 |
| Application number | US-201314065609-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 29, 2013 |
| Priority date | Nov 2, 2009 |
| Publication date | Feb 14, 2017 |
| Grant date | Feb 14, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Cryogranulation systems with improved dispenser assemblies are provided for use in manufacturing frozen pellets of pharmaceutical substances in a fluid medium. Methods of cryogranulating the pharmaceutical substance in the fluid medium are also provided. In particular embodiments, the dispenser assembly is used with suspensions or slurries of pharmaceutical compositions including biodegradable substances, such as proteins, peptides, and nucleic acids. In certain embodiments, the pharmaceutical substance can be adsorbed to any pharmaceutically acceptable carrier particles suitable for making pharmaceutical powders. In one embodiment, the pharmaceutical carrier can be, for example, diketopiperazine-based microparticles. The dispenser assembly improves the physical characteristics of the cryopellets formed and minimizes product loss during processing.
Opening claim text (preview).
The invention claimed is: 1. A composition comprising a plurality of substantially homogeneous frozen pellets of a pharmaceutical composition comprising diketopiperazine microparticles, wherein said composition is formed by dispensing a solution or a suspension of the pharmaceutical composition through a dispenser assembly into a flow of a cooling agent to form the frozen pellets, the dispenser assembly including first and second rows of dispenser ports, the rows of dispenser ports being disposed perpendicularly with respect to the flow of the cooling agent, separating the frozen pellets from the cooling agent by a transport assembly, and transporting the frozen pellets to a pellet receptacle. 2. The composition of claim 1 wherein the pharmaceutical composition further comprises a pharmaceutically active ingredient or agent. 3. The composition of claim 1 , wherein the substantially homogeneous frozen pellets range in diameter from 3-6 mm. 4. The composition of claim 1 , wherein the diketopiperazine has the formula: 5. The composition of claim 2 , wherein the pharmaceutically active agent comprises a peptide, protein or nucleic acid molecule. 6. The composition of claim 2 , wherein the active agent is insulin. 7. The composition of claim 2 , wherein the active agent is GLP-1. 8. The composition of claim 2 , wherein the active agent is oxyntomodulin. 9. The composition of claim 2 , wherein the active agent is parathyroid hormone or calcitonin. 10. The composition of claim 1 , wherein 41% or more of the pellets have diameters greater than 4.75 mm. 11. The composition of claim 1 , wherein 22% or less of the pellets have diameters less than 3.35 mm. 12. A composition comprising a plurality of homogenous frozen pellets comprising diketopiperazine microparticles, the frozen pellets being formed by dispensing a pharmaceutical suspension through a dispenser assembly into a flow of a cooling agent to form the frozen pellets, the dispenser assembly including first and second rows of dispenser ports, the rows of dispenser ports being disposed perpendicularly with respect to the flow of the cooling agent, wherein the dispenser ports of the first and second rows are angled with respect to vertical and wherein the dispenser ports of the first row are disposed at opposite angles with respect to the dispenser ports of the second row, separating the frozen pellets from the cooling agent, and transporting the frozen pellets to a pellet receptacle. 13. The composition of claim 12 , wherein the cooling agent is liquid nitrogen. 14. The composition of claim 12 , wherein the pharmaceutical suspension comprises diketopiperazine-based microparticles in a fluid medium. 15. The composition of claim 13 , wherein the pellets range in diameter from 3-6 mm.
Insulins · CPC title
in a liquid medium · CPC title
Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)} · CPC title
Processes · CPC title
Tubular reactors · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.